Outcomes for FOLFIRI plus bevacizumab or cetuximab in patients treated with oxaliplatin-based adjuvant therapy: A combined analysis of FIRE-3 and CALGB/SWOG 80405 (Alliance)
FOLFIRI 联合贝伐单抗或西妥昔单抗治疗奥沙利铂辅助治疗患者的疗效:FIRE-3 和 CALGB/SWOG 80405 (Alliance) 的联合分析
期刊:European Journal of Cancer
影响因子:7.1
doi:10.1016/j.ejca.2025.115694
Battaglin, Francesca; O'Neil, Bert H; Stintzing, Sebastian; Ou, Fang-Shu; Zemla, Tyler J; Niedzwiecki, Donna; Innocenti, Federico; Hochster, Howard S; von Weikersthal, Ludwig Fischer; Decker, Thomas; Kiani, Alexander; Vehling-Kaiser, Ursula; Heintges, Tobias; Lerchenmüller, Christian; Weiss, Lena; Heinrich, Kathrin; Goldberg, Richard M; Mayer, Robert J; Schilsky, Richard L; Blanke, Charles D; Venook, Alan P; Lenz, Heinz-Josef; Heinemann, Volker